Vasculitis: Inflammation of Blood Vessels

Vasculitis describes a heterogeneous group of disorders defined by inflammatory destruction of blood vessel walls, which disrupts blood flow and causes downstream organ damage. The spectrum ranges from self-limited skin involvement to life-threatening damage of the kidneys, lungs, and nervous system. Understanding vasculitis classification, mechanisms, and clinical boundaries informs appropriate referral to rheumatology specialists and guides timely intervention. Accurate diagnosis depends on integrating clinical presentation, serologic testing, imaging, and tissue biopsy within frameworks developed by named classification bodies.

Definition and Scope

Vasculitis is classified primarily by vessel size — a framework formalized in the 2012 Revised International Chapel Hill Consensus Conference (CHCC) Nomenclature, published in Arthritis & Rheumatism (2013, Vol. 65, No. 1). The CHCC recognized three principal size-based categories: large-vessel vasculitis, medium-vessel vasculitis, and small-vessel vasculitis, with additional categories for variable-vessel and single-organ vasculitis.

Large-vessel vasculitis affects the aorta and its major branches. Giant Cell Arteritis (GCA) is the most common primary systemic vasculitis in adults over age 50, with an estimated incidence of 15–25 per 100,000 persons in that age group according to data cited by the American College of Rheumatology (ACR). Takayasu Arteritis predominantly affects patients under age 40 and most commonly involves the aortic arch branches.

Medium-vessel vasculitis targets the main visceral arteries. Polyarteritis Nodosa (PAN) affects medium muscular arteries without glomerulonephritis or pulmonary capillaritis — a diagnostic boundary that distinguishes it from small-vessel disease. Kawasaki Disease, the leading cause of acquired heart disease in children in high-income countries, affects coronary arteries and predominantly presents before age 5.

Small-vessel vasculitis, the largest category, includes ANCA-associated vasculitides (AAV) — Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), and Eosinophilic Granulomatosis with Polyangiitis (EGPA) — as well as immune complex-mediated forms such as IgA Vasculitis (Henoch-Schönlein Purpura) and cryoglobulinemic vasculitis. For a broader understanding of how the regulatory and professional landscape shapes vasculitis diagnosis and management standards in the United States, institutional guidance from the ACR and the European Alliance of Associations for Rheumatology (EULAR) provides the primary framework.

How It Works

The core mechanism of vasculitis is inflammatory infiltration of the vessel wall. Depending on etiology, the effectors are neutrophils, lymphocytes, macrophages, or giant cells.

In ANCA-associated vasculitis, antineutrophil cytoplasmic antibodies — targeting proteinase-3 (PR3-ANCA, associated with GPA) or myeloperoxidase (MPO-ANCA, associated with MPA) — prime and activate neutrophils, which then adhere to and penetrate vessel endothelium, releasing proteolytic enzymes that destroy vessel walls and provoke fibrinoid necrosis. This process creates the pauci-immune small-vessel destruction that defines AAV on biopsy: glomerular injury without significant complement or immunoglobulin deposition.

In immune complex-mediated vasculitis, circulating antigen-antibody complexes deposit in vessel walls, activate complement, and recruit neutrophils through C3a and C5a signaling. This pattern is seen in IgA vasculitis, where IgA1-dominant complex deposition is found in affected vessels and kidneys.

In large-vessel disease, CD4+ T lymphocytes and macrophages infiltrate the adventitia, organizing into granulomas that ultimately produce luminal stenosis, aneurysm formation, or occlusion. In GCA specifically, dendritic cells in the adventitia are thought to be the initiating stimulus for T-cell recruitment, as described in research published in the Journal of Clinical Investigation.

The downstream consequences follow from the location and degree of vessel narrowing or rupture:

Tissue ischemia — reduced perfusion distal to stenosed segments
Aneurysm formation — weakening of the vessel wall leads to dilation and risk of rupture
Hemorrhage — necrotizing inflammation can erode vessel integrity
Thrombosis — endothelial disruption activates coagulation cascades
Organ failure — kidneys, lungs, peripheral nerves, and skin are the most commonly affected end organs

Common Scenarios

Clinical presentations vary markedly by vessel size and anatomic distribution.

GCA typically presents with new-onset headache, scalp tenderness, jaw claudication, and elevated erythrocyte sedimentation rate (ESR), often exceeding 50 mm/hr. Sudden vision loss, caused by anterior ischemic optic neuropathy, occurs in approximately 15–20% of untreated GCA cases according to ACR educational resources — making it a medical emergency requiring immediate high-dose corticosteroid initiation before biopsy confirmation.

GPA classically presents with upper airway involvement (sinusitis, saddle-nose deformity, subglottic stenosis), lower respiratory disease (pulmonary nodules or hemorrhage), and rapidly progressive glomerulonephritis. PR3-ANCA positivity supports the diagnosis in the appropriate clinical context.

IgA Vasculitis (formerly HSP) presents with a tetrad of palpable purpura on dependent areas, arthritis, abdominal pain, and renal involvement, predominantly in children following upper respiratory infections.

Kawasaki Disease presents with fever lasting 5 or more days plus at least 4 of 5 criteria: bilateral conjunctival injection, oral mucosal changes, polymorphous rash, extremity changes (edema or desquamation), and cervical lymphadenopathy. The ACR and American Heart Association (AHA) jointly maintain guidance on Kawasaki management, including intravenous immunoglobulin (IVIG) and aspirin dosing protocols.

Decision Boundaries

Distinguishing vasculitis from conditions that mimic it — including infection, malignancy, drug reactions, and other inflammatory arthropathies — is a critical diagnostic challenge. The ACR/EULAR classification criteria published between 2022 and 2023 for GPA, MPA, EGPA, PAN, and GCA provide point-based scoring systems intended for research classification, though rheumatologists apply them as diagnostic aids.

Key decision boundaries include:

ANCA-positive vs. ANCA-negative small-vessel disease: ANCA-associated vasculitis is pauci-immune on biopsy; immune complex disease shows complement and immunoglobulin deposits
Primary vs. secondary vasculitis: Secondary forms arise from underlying infection (hepatitis B in PAN, hepatitis C in cryoglobulinemia), connective tissue disease (lupus, rheumatoid arthritis), or drug exposure
Organ-threatening vs. non-organ-threatening disease: This boundary drives treatment intensity — cyclophosphamide or rituximab-based induction versus lower-intensity regimens
Large vs. small vessel: Large-vessel disease rarely causes glomerulonephritis; small-vessel AAV rarely causes large aneurysms

Biopsy confirmation remains the gold standard where accessible — temporal artery biopsy for GCA, kidney biopsy for renal-limited vasculitis, skin biopsy for cutaneous forms. Imaging — including PET-CT for large-vessel involvement and MR angiography — supplements histology when tissue sampling carries prohibitive procedural risk.

Treatment monitoring uses a combination of ANCA titers, inflammatory markers (ESR, CRP), urinalysis, and creatinine to assess remission and detect relapse. The Birmingham Vasculitis Activity Score (BVAS), validated in published clinical trials including those conducted through the European Vasculitis Study Group (EUVAS), provides a standardized instrument for quantifying disease activity across organ domains.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)